West Mifflin, PA

Associates in Ophthalmology Ltd

Geographic Atrophy

Macular Degeneration

Atrophy

Macular Edema

Dry Eye Syndromes

Eye Diseases

Keratoconjunctivitis Sicca

Edema

IONIS-FB-LRx

K-161

Avacincaptad pegol

Ranibizumab

Astellas

Ionis Pharmaceuticals

Kowa

Pfizer

condition

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

The purpose of this study is to assess long-term safety of avacincaptad pegol intravitreal administration for patients with geographic atrophy (GA) who completed Study ISEE2008 (GATHER2) through the Month 24 visit on study treatment (either avacincaptad pegol or Sham).

Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy

Associates in Ophthalmology Ltd | West Mifflin, PA

Site insights

Work at this site?

Active trials

Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy

Trial sponsors